FGF21 and metabolic dysfunction-associated steatohepatitis: In addition, combined therapy with agents targeting single pathogenic processes (e.g., FXR agonist (tropifexor) and CCR2/5 antagonist (cenicriviroc)) could be coupled with novel entries (e.g., GLP1-IgG Fc-FGF21) to produce an efficacious therapeutic approach for treatment of NASH.